Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top executives to monitor ...

The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, ...

A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top executives to monitor the evolving breast cancer competitive intelligence ...

HER2 overexpression is a hallmark of several tumors, including those originating from breast, stomach, bladder, and colon. Patients relapse or become unresponsive to antibody-based regimens ...

Exclusion criteria were the following: non-overexpression of HER2 receptor; cerebral or meningeal metastasis; grade > 1 peripheral neuropathy according to NCI-CTC; severe cardiac dysfunction or ...

"From the excitement of identifying HER2 gene amplification and resultant protein overexpression as a targetable oncogene, through the development of drugs targeting HER2 amplification and ...

"From the excitement of identifying HER2 gene amplification and resultant protein overexpression as a targetable oncogene, through the development of drugs targeting HER2 amplification and ...

“From the excitement of identifying HER2 gene amplification and resultant protein overexpression as a targetable oncogene, through the development of drugs targeting HER2 amplification and ...

This is the largest global assessment of the prevalence of FGFR2b protein overexpression in gastric cancers with ... FGFR2b positive as assessed by IHC in patients known to not be HER2 positive ...